Ponvory 7 MG Oral Tablet

RxCUI: 2532341
RxNorm name: Ponvory 7 MG Oral Tablet
Display name: Ponvory 7 MG Oral Tablet
Full name: Ponvory 7 MG Oral Tablet
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:00

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
PONVORY	PONESIMOD	Vanda Pharmaceuticals Inc.	0c025ba8-ba51-272e-e063-6294a90ad120	2025-12-04	Warnings, Adverse reactions	Exact identifier rxcui: 2532341
PONVORY	PONESIMOD	Janssen Pharmaceuticals, Inc	5be69660-738c-4db7-b0d4-517aa873dc41	2025-04-25	Warnings, Adverse reactions	Exact identifier rxcui: 2532341

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
5be69660-738c-4db7-b0d4-517aa873dc41	Ponvory 7 MG Oral Tablet [PSN] · ponesimod 7 MG Oral Tablet [Ponvory] [SBD] · Ponvory 7 MG Oral Tablet [SY]	3	13	These highlights do not include all the information needed to use PONVORY safely and effectively. See full prescribing information for PONVORY. PONVORY ® (ponesimod) tablets, for oral use Initial U.S. Approval: 2021	20250425
0c025ba8-ba51-272e-e063-6294a90ad120	Ponvory 7 MG Oral Tablet [PSN] · ponesimod 7 MG Oral Tablet [Ponvory] [SBD] · Ponvory 7 MG Oral Tablet [SY]	3	4	These highlights do not include all the information needed to use PONVORY safely and effectively. See full prescribing information for PONVORY. PONVORY ® (ponesimod) tablets, for oral use Initial U.S. Approval: 2021	20251204